Functional neuroimaging in schizophrenia: diagnosis and drug discovery

Philip McGuire; Oliver Howes; James Stone; Paolo Fusar-Poli

doi:10.1016/j.tips.2007.11.005

Functional neuroimaging in schizophrenia: diagnosis and drug discovery

Philip McGuire, Oliver Howes, James Stone, Paolo Fusar-Poli

Research output: Contribution to journal › Article › peer-review

122 Citations (Scopus)

Abstract

Functional neuroimaging provides a direct way of investigating the pathophysiology of schizophrenia in vivo. The function of neurotransmitters implicated in schizophrenia, such as dopamine and glutamate, can be assessed using molecular imaging techniques such as positron emission tomography (PET), single-photon emission tomography (SPET) and magnetic resonance spectroscopy (MRS). Regional brain activity, particularly that associated with the cognitive processes and symptoms associated with the disorder, can be studied using functional magnetic resonance imaging (fMRI). Here, we focus on the potential for the use of these techniques in the diagnosis of schizophrenia and in the development of new drugs for its treatment.

Original language	English
Pages (from-to)	91 - 98
Number of pages	8
Journal	Trends in Pharmacological Sciences
Volume	29
Issue number	2
DOIs	https://doi.org/10.1016/j.tips.2007.11.005
Publication status	Published - Feb 2008

Keywords

Schizophrenia
Magnetic Resonance Imaging
Drug Delivery Systems
Tomography, Emission-Computed, Single-Photon
Positron-Emission Tomography
Humans
Brain Chemistry
Brain
Antipsychotic Agents
Drug Design

Access to Document

10.1016/j.tips.2007.11.005

Cite this

@article{df93a7517cee45f288fd220e719e1fdb,

title = "Functional neuroimaging in schizophrenia: diagnosis and drug discovery",

abstract = "Functional neuroimaging provides a direct way of investigating the pathophysiology of schizophrenia in vivo. The function of neurotransmitters implicated in schizophrenia, such as dopamine and glutamate, can be assessed using molecular imaging techniques such as positron emission tomography (PET), single-photon emission tomography (SPET) and magnetic resonance spectroscopy (MRS). Regional brain activity, particularly that associated with the cognitive processes and symptoms associated with the disorder, can be studied using functional magnetic resonance imaging (fMRI). Here, we focus on the potential for the use of these techniques in the diagnosis of schizophrenia and in the development of new drugs for its treatment.",

keywords = "Schizophrenia, Magnetic Resonance Imaging, Drug Delivery Systems, Tomography, Emission-Computed, Single-Photon, Positron-Emission Tomography, Humans, Brain Chemistry, Brain, Antipsychotic Agents, Drug Design",

author = "Philip McGuire and Oliver Howes and James Stone and Paolo Fusar-Poli",

year = "2008",

month = feb,

doi = "10.1016/j.tips.2007.11.005",

language = "English",

volume = "29",

pages = "91 -- 98",

journal = "Trends in Pharmacological Sciences",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Functional neuroimaging in schizophrenia

T2 - diagnosis and drug discovery

AU - McGuire, Philip

AU - Howes, Oliver

AU - Stone, James

AU - Fusar-Poli, Paolo

PY - 2008/2

Y1 - 2008/2

N2 - Functional neuroimaging provides a direct way of investigating the pathophysiology of schizophrenia in vivo. The function of neurotransmitters implicated in schizophrenia, such as dopamine and glutamate, can be assessed using molecular imaging techniques such as positron emission tomography (PET), single-photon emission tomography (SPET) and magnetic resonance spectroscopy (MRS). Regional brain activity, particularly that associated with the cognitive processes and symptoms associated with the disorder, can be studied using functional magnetic resonance imaging (fMRI). Here, we focus on the potential for the use of these techniques in the diagnosis of schizophrenia and in the development of new drugs for its treatment.

AB - Functional neuroimaging provides a direct way of investigating the pathophysiology of schizophrenia in vivo. The function of neurotransmitters implicated in schizophrenia, such as dopamine and glutamate, can be assessed using molecular imaging techniques such as positron emission tomography (PET), single-photon emission tomography (SPET) and magnetic resonance spectroscopy (MRS). Regional brain activity, particularly that associated with the cognitive processes and symptoms associated with the disorder, can be studied using functional magnetic resonance imaging (fMRI). Here, we focus on the potential for the use of these techniques in the diagnosis of schizophrenia and in the development of new drugs for its treatment.

KW - Schizophrenia

KW - Magnetic Resonance Imaging

KW - Drug Delivery Systems

KW - Tomography, Emission-Computed, Single-Photon

KW - Positron-Emission Tomography

KW - Humans

KW - Brain Chemistry

KW - Brain

KW - Antipsychotic Agents

KW - Drug Design

U2 - 10.1016/j.tips.2007.11.005

DO - 10.1016/j.tips.2007.11.005

M3 - Article

C2 - 18187211

VL - 29

SP - 91

EP - 98

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 2

ER -

Functional neuroimaging in schizophrenia: diagnosis and drug discovery

Abstract

Keywords

Access to Document

Fingerprint

Cite this